[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6219 followers
Created: 2025-07-28 12:18:27 UTC

Bharat Parenterals Q1FY26 Results & Expansion Plans 📊 | MCap XXXXXXXX Cr

- Standalone Q1FY26 revenue: ₹94.37 Crores, net profit: ₹10 Crores
- Consolidated Q1FY26 revenue: ₹116 Crores, net loss: ₹87 Lakhs
- FY26 outlook: 12-14% standalone revenue growth, 15-17% EBITDA margin target
- Innoxel Lifesciences expanding product pipeline
- Varenyam Biolifesciences facility under construction
- Varenyam Healthcare targeting ₹62-65 Crores revenue
- Mr. Sanjay Shah resigns as Non-Executive Non-Independent Director
- Mr. Alkesh Jayantilal Shah appointed as Additional Non-Executive Non-Independent Director (effective July 28, 2025)
- Mr. Mukeshbhai Patel re-appointed as Non-Executive Independent Director (effective September 25, 2025)
- M/s. Shah Mehta & Bakshi proposed as new Statutory Auditors

Complete Source:

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

Preview 👇 (First X out of XX pages)

![](https://pbs.twimg.com/media/Gw8aq6cbQAAO10b.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1949806655761498586/c:line.svg)

**Related Topics**
[quarterly earnings](/topic/quarterly-earnings)
[mcap](/topic/mcap)
[investment](/topic/investment)

[Post Link](https://x.com/_Investor_Feed_/status/1949806655761498586)